G1 Therapeutics price target lowered to $50 from $55 at Wedbush » 08:4507/0107/01/20
Wedbush analyst David…
Wedbush analyst David Nierengarten lowered the firm's price target on G1 Therapeutics to $50 from $55 and keeps an Outperform rating on the shares. The analyst notes that the company entered into a co-promotion agreement with Boehringer Ingelheim for trila in small cell lung cancer in the U.S. and Puerto Rico and completed the NDA submission. A commercial partner for trila was long-awaited and Nierengarten views the agreement with BI as a win for G1 Therapeutics, which should facilitate a successful initial launch for trila in SCLC pending a likely approval next year. Appreciably, the agreement with BI leaves the door open for additional commercial partnership opportunities down the road likely to time around topline trila readouts of the Phase 2 I-SPY2 trial in breast cancer and Phase 3 trial in colorectal cancer, he adds. The analyst notes that thanges in his price target are due in part to pushing out the expected launch for trila ex-U.S. and the partnership with BI not being a more traditional pharma license where G1 would receive upfront payments and downstream royalties.
G1 Therapeutics, Boehringer announce co-promotion agreement for trilaciclib » 16:1706/3006/30/20
G1 Therapeutics and…
G1 Therapeutics and Boehringer Ingelheim announced that the companies have entered into a co-promotion agreement for trilaciclib in the United States and Puerto Rico. Under the terms of the three-year agreement, G1 and Boehringer Ingelheim will collaborate on the commercialization of trilaciclib for its first potential indication in small cell lung cancer, or SCLC, with the Boehringer Ingelheim oncology commercial team. Discovered and developed by G1, trilaciclib is an investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy. Under the terms of the agreement, G1 will book revenue in the United States and Puerto Rico and retain global development and commercialization rights to trilaciclib. In the U.S. and Puerto Rico, G1 will lead marketing, market access and medical engagement initiatives; Boehringer Ingelheim will lead sales force engagements. G1 will make initial payments to Boehringer Ingelheim to cover start-up expenses and pre-approval initiatives to support a successful commercial launch. G1 will pay a promotion fee of a mid-twenties percentage of net sales in the first year of commercialization, which decreases to a low double-digit/high single-digit percentage in the second and third years of commercialization, respectively. There are no payments due by either party beyond the expiration of the three-year term of the agreement. The agreement does not extend to additional indications that G1 may pursue for trilaciclib.
|Over a week ago|
G1 Therapeutics initiated with a Buy at Roth Capital » 09:1406/2606/26/20
Roth Capital analyst Tony…
Roth Capital analyst Tony Butler initiated coverage of G1 Therapeutics with a Buy rating and $55 price target. The company expects to complete filing an NDA for lead drug, trilaciclib, in small-cell lung cancer by Q2 for a 2021 U.S. launch while it is also developing rintodestrant for ER+/HER2- breast cancer, noted Butler.
G1 Therapeutics, Genor Biopharma announce license agreement for lerociclib » 06:0906/2206/22/20
G1 Therapeutics and Genor…
G1 Therapeutics and Genor Biopharma Co. announced an exclusive license agreement for the development and commercialization of lerociclib in the Asia-Pacific region (excluding Japan). Under the terms of the agreement, G1 will receive an upfront cash payment of $6M and be eligible to receive up to an additional $40M in development and commercial milestone payments. In addition, Genor will pay G1 tiered royalties ranging from high single to low double-digits based on annual net sales of lerociclib. Genor will have exclusive development and commercialization rights for lerociclib in the Asia-Pacific region (excluding Japan).
|Over a month ago|
G1 Therapeutics participates in a conference call with JPMorgan » 10:4606/0206/02/20
JPMorgan SMid Cap Biotech…
JPMorgan SMid Cap Biotech Analyst Rama, along with CEO Velleca and CMO Malik, provides perspectives on Trilaciclib and broader pipeline post-ASCO's recently-held Annual Virtual Meeting on a conference call to be held on June 2 at 12 pm hosted by JPMorgan.
JonesTrading sees potential positive myelopreservation data in June for Aileron » 11:4705/2705/27/20
JonesTrading analyst Soumit Roy reiterates a Buy rating and a $5 price target on Aileron Therapeutics (ALRN) after the company guided for early myelopreservation data in June. He expects to see positive data from 11 patients in TP53 mutant 2L SCLC when treated with topotecan, and could see a 50% reduction in the rates of severe anemia and thrombocytopenia, which would be markedly better than peer G1 Therapeutics (GTHX) showing 24% reduction in anemia and 0% reduction in thrombocytopenia. Enrollment has initiated in dose expansion to enroll eight patients and complete data to be presented in Q4, Roy adds.
G1 Therapeutics to present data showing benefits of Trilaciclib in SCLC » 17:3205/1305/13/20
G1 Therapeutics announced…
G1 Therapeutics announced that data across three randomized, double-blind, placebo-controlled Phase 2 trials of the investigational therapy trilaciclib in small cell lung cancer will be presented on May 29 at the ASCO20 Virtual Scientific Program of the American Society of Clinical Oncology. In these trials, trilaciclib was administered prior to chemotherapy treatment and significantly reduced rates of myelosuppression and the need for related supportive care interventions compared with patients receiving chemotherapy treatment alone. In addition, two abstracts on the real-world burden of chemotherapy-induced myelosuppression will be published. Myelosuppression is the result of damage to bone marrow cells, and is one of the most common side effects of chemotherapy. Myelosuppression often requires the administration of rescue interventions such as growth factors and blood or platelet transfusions, and may also result in chemotherapy dose delays and reductions. Immune cell damage may decrease the ability of the immune system to fight the cancer, as well as infection. Trilaciclib is a first-in-class investigational therapy designed to preserve bone marrow and immune system function during chemotherapy and improve patient outcomes. The company plans to complete an NDA submission for trilaciclib for myelopreservation in SCLC in 2Q20. Trilaciclib has been assigned Breakthrough Therapy Designation by the FDA.
G1 Therapeutics reports Q1 EPS (82c), consensus (98c) » 16:1005/0605/06/20
We have activated…
We have activated business continuity plans in response to the COVID-19 pandemic to ensure we can advance therapies that patients with cancer, their families, and healthcare providers are counting on to improve outcomes, and also taken actions to safeguard the well-being of our employees," said Mark Velleca, M.D., Ph.D., Chief Executive Officer. "We are on track to complete a New Drug Application filing for trilaciclib for patients with small cell lung cancer this quarter, and have initiated virtual medical education programs as we prepare for commercial launch in the U.S. We remain committed to evaluating the benefits of trilaciclib in other indications and expect to initiate the I SPY-2 breast cancer trial this quarter and a pivotal trial in colorectal cancer in the fourth quarter of 2020. Cancer patients experiencing chemotherapy-induced myelosuppression are an especially vulnerable population, and trilaciclib has the potential to be the first proactively administered myelopreservation therapy for these patients." Cash and cash equivalents totaled $242.4 million as of March 31, 2020, compared to $269.2 million as of December 31, 2019.
Eyeforpharma to hold a virtual conference » 07:5304/1504/15/20
ABBV, ABEO, ALKS, AMGN, AMRN, AZN, BAYRY, BIIB, CRM, DIS, ESALY, FB, GSK, GTHX, LLY, MNK, MRK, MSFT, NVO, NVS, OTSKY, PFE, SEPR, SGEN, SNY, SYNH, TAK
Eyeforpharma Philadelphia will be held virtually on April 14-17 with webcasts starting at 9 am each day. Webcast Link
|Over a quarter ago|
NextCure appoints Garry Nicholson to board of directors » 07:4303/3003/30/20
NextCure (NXTC) announced…
NextCure (NXTC) announced the appointment of Garry Nicholson to its board of directors. In addition, Timothy M. Shannon, M.D. notified NextCure that he is stepping down from the company's board of directors. Nicholson currently serves as chairman of the board for G1 Therapeutics (GTHX) and as a board member for Turning Point Therapeutics, Five Prime Therapeutics, Personal Genome Diagnostics and Tmunity Therapeutics.